1. Home
  2. TARS

as of 12-09-2025 3:45pm EST

$80.05
$2.19
-2.66%
Stocks Health Care Medicinal Chemicals and Botanical Products Nasdaq

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.

Chart Type:
Time Range:
Founded: 2016 Country:
United States
United States
Employees: N/A City: IRVINE
Market Cap: 2.8B IPO Year: 2020
Target Price: $76.56 AVG Volume (30 days): 376.9K
Analyst Decision: Strong Buy Number of Analysts: 9
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.99 EPS Growth: N/A
52 Week Low/High: $38.51 - $85.25 Next Earning Date: 11-04-2025
Revenue: $366,100,000 Revenue Growth: 182.44%
Revenue Growth (this year): 147.24% Revenue Growth (next year): 53.11%

AI-Powered TARS Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 2 days ago

AI Recommendation

hold
Model Accuracy: 79.05%
79.05%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Tarsus Pharmaceuticals Inc. (TARS)

Azamian Bobak R.

President/CEO and Board Chair

Sell
TARS Sep 24, 2025

Avg Cost/Share

$55.37

Shares

6,000

Total Value

$332,220.00

Owned After

812,106

SEC Form 4

Share on Social Networks: